PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26683659-8	2016	Dexmedetomidine pretreatment effectively improved histological outcome and restored levels of caspase-3, the Bax/Bcl-2 ratio, NF-kappaB, and COX-2.	Dexmedetomidine	0-15	caspase 3	Mus musculus	94-103	
29566706-20	2018	Dexmedetomidine increased p-Akt in a time- and dose-dependent manner, and down-regulated the expression of caspase 3 and Bax and up-regulated the Bcl-2 expression in PMVECs.	Dexmedetomidine	0-15	caspase 3	Mus musculus	107-116	
29351316-12	2018	The mRNA expression of TNF-alpha, MCP-1, indoleamine 2, 3 dioxygenase (IDO), caspase-3, and iNOS were increased in the brain of LPS-challenged mice, which were reduced by Dex but not vehicle.	Dexmedetomidine	171-174	caspase 3	Mus musculus	77-86	
28784305-9	2017	Moreover, suppression of oxidative stress and apoptosis was observed in DEX-treated mice with I/R injury, probably through enhancing nuclear factor erythroid 2-related factor 2 (Nrf2), reducing mitogen-activated protein kinases (MAPKs) and Caspase-3/poly (ADP-ribose) polymerase (PARP) pathways.	Dexmedetomidine	72-75	caspase 3	Mus musculus	240-278	
27987330-9	2017	The dexmedetomidine-involved neuroprotection was further confirmed in the other NB41A3 neuronal cells by significantly attenuating I/R-induced changes in the MMP, caspase-3 activation, DNA fragmentation, and cell apoptosis.	Dexmedetomidine	4-19	caspase 3	Mus musculus	163-172	
30856162-13	2019	Moreover, dexmedetomidine ameliorated the altered activity of caspase-3, caspase-8, and caspase-9 enzyme in the lung tissues of CLP-induced lung injure mice.	Dexmedetomidine	10-25	caspase 3	Mus musculus	62-71	
28224201-10	2017	Mice treated with DEX exhibited less apoptotic tubular cells in response to cisplatin insult, which was associated with decreased Bax and reduced activation of p53 and caspase-3.	Dexmedetomidine	18-21	caspase 3	Mus musculus	168-177	
31030092-7	2019	In addition, pre-treatment with DEX down-regulated the expression of cleavage of caspase-3, decreased the activities of caspase-3, caspase-8, caspase-9, and consequently, reduced hepatocyte apoptosis.	Dexmedetomidine	32-35	caspase 3	Mus musculus	81-90	
33782744-8	2021	TUNEL staining and the protein expression levels of cleaved caspase-3 and cleaved caspase-9 were used to detect cell apoptosis and results make clear that DEX can reduce the apoptosis caused by myocardial infarction.	Dexmedetomidine	155-158	caspase 3	Mus musculus	60-69	
35199933-9	2022	In comparison with the DEX group, mice in the DEX + MALAT1 group had larger tumors, with the up-regulation of Ki-67 and the down-regulation of active caspase-3.	Dexmedetomidine	23-26	caspase 3	Mus musculus	150-159	
35199933-9	2022	In comparison with the DEX group, mice in the DEX + MALAT1 group had larger tumors, with the up-regulation of Ki-67 and the down-regulation of active caspase-3.	Dexmedetomidine	46-49	caspase 3	Mus musculus	150-159	
31682847-11	2019	Consistently, transcription and protein levels of genes such as TLR4, MYD88, MTA1, PTGS2, CASP3 associated with NF-kappaB signaling pathway were all compromising after treated with DEX or KDM5A-IN-1 groups compared to AKI group.	Dexmedetomidine	181-184	caspase 3	Mus musculus	90-95	
33821300-6	2021	DEX also markedly attenuated the increases in malondialdehyde 5 (MDA 5) and inositol-dependent enzyme a (IRE-a), attenuated the decrease in superoxide dismutase 1(SOD-1), reversed the low expression of B-cell lymphoma-2 (Bcl-2), and the high expressions of Bax and Caspase-3.	Dexmedetomidine	0-3	caspase 3	Mus musculus	265-274	
33179100-11	2021	Dexmedetomidine significantly decreased the expression of activated caspase-3 following sevoflurane exposure.	Dexmedetomidine	0-15	caspase 3	Mus musculus	68-77	
31030092-7	2019	In addition, pre-treatment with DEX down-regulated the expression of cleavage of caspase-3, decreased the activities of caspase-3, caspase-8, caspase-9, and consequently, reduced hepatocyte apoptosis.	Dexmedetomidine	32-35	caspase 3	Mus musculus	120-129